|Table of Contents|

Advances in treatment of gastrointestinal diffuse large B-cell lymphoma and related potential prognostic factors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 03
Page:
580-584
Research Field:
Publishing date:

Info

Title:
Advances in treatment of gastrointestinal diffuse large B-cell lymphoma and related potential prognostic factors
Author(s):
LI Xixi; QIN Ling
College of Clinical Medicine,the First Affiliated Hospital of Henan University of Science and Technology,Henan Luoyang 471003,China.
Keywords:
gastrointestinal; diffuse large B-cell lymphoma; treatment; prognosis
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2023.03.038
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL).It is a medium to high-grade malignant lymphoma with a high incidence in adults.Most of the clinical manifestations are invasive disease course,and most of them are painless and progressively enlarged lymph nodes,but they can also be expressed outside the nodules.Among them,the most likely site of DLBCL is the gastrointestinal tract.Although the treatment of DLBCL has gradually been standardized,because of the hidden onset of the gastrointestinal tract,the clinical symptoms are not typical,there is no unified standard for its treatment,and there are many factors affecting its survival prognosis,so in order to improve the clinical understanding of this disease in order to formulate treatment plans and evaluate the survival prognosis for different people,we now review the selection of treatment methods and the latest progress of related factors that affect the prognosis.

References:

［1］李晔雄.胃肠道淋巴瘤放疗进展［J］.中华结直肠疾病电子杂志,2016,5(2):114-120. LI YX.Recent progress in radiation therapy for primary gastrointestinal lymphoma［J］.Chinese Journal of Colorectal Diseases,2016,5(2):114-120.
［2］刘祥祥,王健红,郝彩霞,等.17例原发胃肠道弥漫大B细胞淋巴瘤临床病例分析［J］.现代肿瘤医学,2018,26(17):2756-2759. LIU XX,WANG JH,HAO CX,et al.Clinical analysis of 17 cases of primary gastrointestinal diffuse large B-cell lymphoma［J］.Modern Oncology,2018,26(17):2756-2759.
［3］SHEN Y,OU J,WANG B,et al.Influence of severe gastrointestinal complications in primary gastrointestinal diffuse large B-cell lymphoma［J］.Cancer Management and Research,2021,13:1041-1052.
［4］LIGHTNER AL,SHANNON E,GIBBONS MM,et al.Primary gastrointestinal non-Hodgkin's lymphoma of the small and large intestines:A systematic review［J］.Journal of Gastrointestinal Surgery,2016,20(4):827-839.
［5］SOHN BS,KIM S,YOON DH,et al.The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma［J］.Annals of Hematology,2012,91(11):1731-1739.
［6］黄海雯,蒋亦彬,付天文,等.外科手术及利妥昔单抗对原发胃弥漫大B细胞淋巴瘤患者生存的影响［J］.中华血液学杂志,2016,37(7):602-606. HUANG HW,JIANG YB,FU TW,et al.Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma［J］.Chinese Journal of Hematology,2016,37(7):602-606.
［7］ZHANG ST,WANG L,YU D,et al.Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach:an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution［J］.World Journal of Surgical Oncology,2015,13:246.
［8］毛蕾,王希,王超雨,等.原发胃肠道弥漫大B细胞淋巴瘤分期系统比较及预后分析［J］.中华医学杂志,2019,99(24):1853-1858. MAO L,WANG X,WANG CY,et al.Evaluation of different staging systems and prognostic analysis of primary gastrointestinal diffuse large B cell lymphoma［J］.National Medical Journal of China,2019,99(24):1853-1858.
［9］SURESH B,ASATI V,LAKSHMAIAH KC,et al.Primary gastrointestinal diffuse large B-cell lymphoma:A prospective study from South India［J］.South Asian Journal of Cancer,2019,8(1):57.
［10］NOWAKOWSKI GS,LAPLANT B,MACON WR,et al.Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma:a phase II study［J］.Journal of Clinical Oncology,2015,33(3):251-257.
［11］WINTER AM,LANDSBURG DJ,MATO AR,et al.A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib［J］.Blood,2017,130(14):1676-1679.
［12］ISHIKAWA E,NAKAMURA M,SHIMADA K,et al.Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma［J］.Journal of Gastroenterology,2019,55(1):39-50.
［13］SCHUSTER S,BISHOP MR,TAM C,et al.Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL):An interim analysis［J］.Clinical Lymphoma Myeloma and Leukemia,2017,17:S373-S374.
［14］LIN JL,LIN JX,LI P,et al.The impact of surgery on long-term survival of patients with primary gastric diffuse large B-cell lymphoma:A SEER population-based study［J］.Gastroenterology Research and Practice,2019,2019:1-8.
［15］WANG M,MA S,SHI W,et al.Surgery shows survival benefit in patients with primary intestinal diffuse large B-cell lymphoma:A population-based study［J］.Cancer Medicine,2021,10(10):1-12.
［16］FAN X,ZANG L,ZHAO BB,et al.Development and validation of prognostic scoring in primary intestinal diffuse large B-cell lymphoma:a single-institution study of 184 patients［J］.Annals of Translational Medicine,2021,9(20):1542-1547.
［17］ WANG J,ZHOU M,ZHOU R,et al.Nomogram for predicting the overall survival of adult patients with primary gastrointestinal diffuse large B cell lymphoma:A SEER-based study［J］.Frontiers in Oncology,2020,10(3):1093-1100.
［18］FERRERI AJM,GOVI S,PONZONI M.The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach［J］.Current Opinion in Oncology,2013,25(5):470-479.
［19］SANTOS LVD,LIMA JOPD,LIMA CSP,et al.Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma:A systematic review with meta-analysis［J］.BMC Cancer,2012,12:288.
［20］CHEN H,WANG X,WANG J,et al.Quality of life in patients with breast cancer and their rehabilitation needs［J］.Pakistan Journal of Medical Sciences,2014,30(1):126-130.
［21］ZHANG X,WANG P,ZHAO L,et al.Risk factors and patterns of lymph node involvement in primary gastric large B-cell lymphoma:implications for target definition［J］.OncoTargets and Therapy,2016,9:4757-4762.
［22］GAO F,WANG ZF,TIAN L,et al.A prognostic model of gastrointestinal diffuse large B cell lymphoma［J］.Medical Science Monitor,2021,27(27):898-905.
［23］CHU Y,ZHOU XX,LIU YY,et al.Systemic inflammation response index (SIRI) predicts clinical outcome and improves NCCN-IPI scoring in primary gastrointestinal diffuse large B-cell lymphoma［J］.Blood,2021,138(S1)：1432-1438.
［24］代冠荣,夏瑞祥,刘沁华.原发胃肠道弥漫大B细胞淋巴瘤的临床预后因素分析［J］.安徽医科大学学报,2021,56(9):1496-1504. DAI GR,XIA RX,LIU QH.Clinical prognostic factors of primary gastrointestinal diffuse large B-cell lymphoma［J］.Journal of Anhui Medical University,2021,56(9):1496-1504.
［25］KUMAR A,LUNNING MA,ZHANG Z,et al.Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era［J］.British Journal of Haematology,2015,171(5):776-783.
［26］LU TX,MIAO Y,WU JZ,et al.The distinct clinical features and prognosis of the CD10+MUM1+ and CD10-Bcl6-MUM1- diffuse large B-cell lymphoma［J］.Scientific Reports,2016,6:20465.
［27］江茂情,阮新忠,陈萍,等.胃肠道弥漫大B细胞淋巴瘤的免疫表型和治疗方案与预后的关系［J］.中华消化杂志,2019,39(2):88-93. JIANG MQ,RUAN XZ,CHEN P,et al.Correlation between the immunophenotypes,treatment strategies and prognosis of gastrointestinal diffuse large B-cell lymphoma［J］.Chinese Journal of Digestion,2019,39(2):88-93.
［28］CHEN L,KAN Y,WANG X,et al.Overexpression of microRNA130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma［J］.Oncology Letters,2020,20(4):1-12.
［29］ WANG XY,KAN YT,CHEN LY,et al.miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma［J］.Oncology Letters,2020,19(5):3487-3494.
［30］ XIA B,ZHANG L,GUO SQ,et al.Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma［J］.World Journal of Gastroenterology,2015,21(8):2433-2442.
［31］林剑扬,郑艳彬,何鸿鸣,等.甲基转移酶EZH2表达水平对原发性胃肠道弥漫大B细胞淋巴瘤患者临床疗效及远期预后的预测价值分析［J］.中国实验血液学杂志,2021,29(3):1-6. LIN JY,ZHENG YB,HE HM,et al.Expression of methyltransferase EZH2 in patients with primary gastrointestinal diffuse large B-cell lymphoma and its prognostic value［J］.Chinese Journal of Experimental Hematology,2021,29(3):1-6.
［32］QIAN Z,CHEN L,WANG X,et al.Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma［J］.Springer International Publishing,2021,22(2):183-191.
［33］CHEN F,LIU SQ,ZHOU Y,et al.Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma［J］.Hematology (Amsterdam,Netherlands),2016,21(7):399-403.
［34］MASAYOSHI F,KATSUYOSHI T,SHIH-SUNG C,et al.A20 (TNFAIP3) alterations in primary intestinal diffuse large B-cell lymphoma［J］.Acta Medica Okayama,2018,72(1):3-30.
［35］GEHONG D,ESTELLE C,NAIYAN Z,et al.A20,ABIN-1/2,and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma［J］.Clinical Cancer Research,2011,17(6):1440-1451.

Memo

Memo:
-
Last Update: 1900-01-01